Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure

Circulation: Heart Failure

Volumn 6, Issue 1, 2013, Pages 91-98

  Askevold, Erik Tandberg ^a,k   Nymo, Stale ^b   Ueland, Thor ^c   Gravning, Jorgen ^d   Wergeland, Ragnhild ^e   Kjekshus, John ^a   Yndestad, Arne ^f   Cleland, John G F ^g   McMurray, John J V ^h   Aukrust, Pal ⁱ   Gullestad, Lars ^j  

^a Department of Cardiology ^*  (United Kingdom)

^b Research Institute of Internal Medicine   (United Kingdom)

^c Section of Clinical Immunology and Infectious Diseases   (United Kingdom)

^d Institute for Surgical Research   (United Kingdom)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g Jebsen Cardiac Research Centre   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ CASTLE HILL HOSPITAL   (United Kingdom)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Heart failure; Interleukin 6; Mortality; Risk assessment; Soluble glycoprotein 130

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GLYCOPROTEIN; INTERLEUKIN 6; ROSUVASTATIN; SOLUBLE GLYCOPROTEIN 130; TROPONIN T; UNCLASSIFIED DRUG;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOASSAY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC HEART FAILURE;

EID: 84873661780     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.972653     Document Type: Article

References (26)

1. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss HP, Tschöpe C, Van Bilsen M, Zannad F, McMurray J, Shah AM. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119-129.
2. Yndestad A, Damås JK, Øie E, Ueland T, Gullestad L, Aukrust P. Role of inflammation in the progression of heart failure. Curr Cardiol Rep. 2007;9:236-241.
3. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: Contribution of wound healing and inflammation. Cardiovasc Res. 2009;81:474-481.
4. Mann DL. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
5. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: The gp130-STAT axis. Basic Res Cardiol. 2007;102:393-411.
6. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95-103.
7. Hirota H, Izumi M, Hamaguchi T, Sugiyama S, Murakami E, Kunisada K, Fujio Y, Oshima Y, Nakaoka Y, Yamauchi-Takihara K. Circulating interleukin-family cytokines and their receptors in patients with congestive heart failure. Heart Vessels. 2004;19:237-241.
8. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
9. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Fujii M, Matsumoto T, Yamamoto T, Wang X, Asai S, Tsuji T, Tanaka H, Saito Y, Kuwahara K, Nakao K, Kinoshita M. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;38:1485-1490.
10. Hingorani AD, Casas JP, Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: A Mendelian randomisation analysis. Lancet. 2012;379:1214-1224.
11. Sarwar N, Butterworth AS, IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213.
12. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:376-382.
13. Gwechenberger M, Pacher R, Berger R, Zorn G, Moser P, Stanek B, Huelsmann M. Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression. J Heart Lung Transplant. 2005;24:2190-2195.
14. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261.
15. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: Prediction of cardiovascular events and interaction with the effects of rosuvastatin: A report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009;54:1850-1859.
16. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A retrospective analysis. Circulation. 2009;120:2188-2196.
17. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F; CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): Incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail. 2009;11:281-291.
18. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med. 2010;48:1703-1711.
19. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
20. Petretta M, Condorelli GL, Spinelli L, Scopacasa F, de Caterina M, Leosco D, Vicario ML, Bonaduce D. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am Heart J. 2000;140:E28.
21. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, Gullestad L, Damås JK. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol. 2008;28:1909-1919.
22. Jostock T, Müllberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem. 2001;268:160-167.
23. Fischer P, Hilfiker-Kleiner D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects. Br J Pharmacol. 2008;153(suppl 1):S414-S427.
24. Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, Müller W, Scherr M, Theilmeier G, Ernst M, Hilfiker A, Drexler H. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122:145-155.
25. Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, Bavendiek U, von Felden J, Divchev D, Kempf T, Wollert KC, Seegert D, Rose-John S, Tietge UJ, Schieffer B, Grote K. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32:281-290.
26. Yamamoto K, Rose-John S. Therapeutic blockade of interleukin-6 in chronic inflammatory disease. Clin Pharmacol Ther. 2012;91:574-576.